Clinuvel Pharmaceuticals CEO Philippe Wolgen must be a serious flight risk.
How else to explain the spoils that year upon year accrue for the “unusual”, “amazing” and “extraordinary” executive (his chairman’s words). For the second year running, Wolgen’s cash take alone has equated to more than 5 per cent of the company’s annual revenues.
Loading...
Myriam Robin is a senior writer based in the Melbourne newsroom. She has previously been a Rear Window columnist and editor, and before that reported on financial markets and media. Connect with Myriam on Twitter. Email Myriam at myriam.robin@afr.com
